A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

NCT06065748 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1050

Enrollment

INDUSTRY

Sponsor class

Conditions

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Interventions

DRUG: Giredestrant
DRUG: Fulvestrant
DRUG: Abemaciclib
DRUG: Palbociclib
DRUG: Ribociclib
DRUG: LHRH Agonist
DIAGNOSTIC_TEST: FoundationOne Liquid CDx Assay (F1LCDx)

Sponsor

Hoffmann-La Roche